Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177255 · ClinicalTrials.gov registry record · Phase 2
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers
A Phase 2 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00177255 is a Phase 2 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 40 participants.
The verdict
NCT00177255, a Phase 2 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas.
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177255
The ClinicalTrials.gov registry entry for NCT00177255 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00177255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177255 about?
NCT00177255 is a clinical study titled "A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers". This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas.
What is the current status of trial NCT00177255?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00177255?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00177255?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.